Pfizer has lifted its bid for COVID testing app developer ResApp Health, marking the fourth time the big pharma company has altered its offer.
Pfizer is now offering 20.8c a share, up from 14.6c.
Pfizer?s initial 20.7c a share offer was revised down to 14.6c a share after ResApp?s smartphone-based COVID screening test failed a critical test.
The revised bid caused ResApp?s shares to surge more than 50%.